gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate has been researched along with Drug-Related Side Effects and Adverse Reactions in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alison, D; Bacigalupo, L; Billiouw, JM; Boffa, JJ; Campioni, P; Deray, G; Devos, D; Ferreiros, J; Glowacki, F; Hannedouche, T; Maes, B; Marti-Bonmati, L; Rigothier, C; Rouviere, O; Vrtovsnik, F | 1 |
| Bonnemain, B; Bourrinet, P; Champeroux, P; Drici, M; El Amrani, AI; Fauchou, N; Gaillard, S; Le Coz, F; Martel, E; Richard, S | 1 |
2 trial(s) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study).
Topics: Acute Kidney Injury; Aged; Contrast Media; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Male; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Prevalence; Renal Insufficiency, Chronic; Risk Factors; Treatment Outcome | 2013 |
Cardiovascular safety of gadoterate meglumine (Gd-DOTA).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Blood Pressure; Cardiovascular Diseases; Contrast Media; Dogs; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Heart; Heart Rate; Heterocyclic Compounds; Humans; Male; Middle Aged; Organometallic Compounds; Risk Assessment | 2007 |